Contact

Rootwake Home About Services Safety & Risks Research & Policy Timeline Clinical Evidence Review Contact Rootwake / independent resource Ibogaine Drug A plainspoken guide to ibogaine’s cultural context, emerging research, legal status, and serious safety considerations. Safety before hype First, the plain version. Ibogaine is not a routine medicine, a simple detox, or a risk-free shortcut. Its public profile is rising faster than the evidence and safety systems needed to support broad use. what it is / what it is not Ibogaine is a naturally occurring psychoactive indole alkaloid found in the root bark of Tabernanthe iboga and related plants. It can produce prolonged, dream-like psychoactive effects and is often described as a dissociative or psychedelic compound. A useful starting point is the broad overview of ibogaine’s chemistry and history , while its cultural context includes long-standing ceremonial use in Central and West African traditions, especially Bwiti-related practices. Modern medical interest centers on opioid withdrawal interruption, craving reduction, and possible effects on PTSD, depression, traumatic brain injury, and other addiction-related conditions. That interest does not settle the question of effectiveness. The strongest point of agreement is that ibogaine carries serious cardiac risk, including QT prolongation and arrhythmia risk. In the United States, ibogaine remains a Schedule I controlled substance. The DEA’s drug scheduling framework explains the federal category; research activity, public advocacy, and policy discussion do not make general use legal. why 2026 is loud Policy movement is real. Certainty is not. Ibogaine has moved from marginal interest to active policy and research conversation. Federal attention, reported FDA facilitation of potential U.S. trials, and state-backed programs have made the subject more visible. Texas committed $50 million to ibogaine research in 2025–2026 reporting, while Arizona also backed relate

Contact

Published channels, when available.